Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer.
Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. Nickols NG, et al. Among authors: reiter re. Eur Urol. 2024 Aug;86(2):190-193. doi: 10.1016/j.eururo.2024.02.008. Epub 2024 Mar 14. Eur Urol. 2024. PMID: 38490853 Clinical Trial. No abstract available.
Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography.
Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. Smith CP, et al. Among authors: reiter re. Eur Urol Oncol. 2023 Apr;6(2):224-227. doi: 10.1016/j.euo.2023.02.009. Epub 2023 Mar 2. Eur Urol Oncol. 2023. PMID: 36870853
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Seifert R, et al. Eur Urol. 2023 May;83(5):405-412. doi: 10.1016/j.eururo.2023.02.002. Epub 2023 Mar 17. Eur Urol. 2023. PMID: 36935345 Free article. Review.
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, Davicioni E, Spratt DE, Attard G, Lotan TL, Lee Kiang Chua M, Sweeney CJ, Schaeffer EM. Weiner AB, et al. Among authors: reiter re. Cancer. 2023 Jul 15;129(14):2169-2178. doi: 10.1002/cncr.34790. Epub 2023 Apr 14. Cancer. 2023. PMID: 37060201 Free article.
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial.
Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Djaïleb L, et al. Among authors: reiter re. Eur Urol. 2023 Dec;84(6):588-596. doi: 10.1016/j.eururo.2023.06.022. Epub 2023 Jul 21. Eur Urol. 2023. PMID: 37482512 Clinical Trial.
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADAR.
Ong WL, Nikitas J, Joseph D, Steigler A, Millar J, Valle L, Steinberg ML, Ma TM, Reiter RE, Rettig MB, Nickols NG, Chang A, Zaorsky NG, Spratt DE, Romero T, Kishan AU. Ong WL, et al. Among authors: reiter re. Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):813-825. doi: 10.1016/j.ijrobp.2023.09.051. Epub 2023 Oct 4. Int J Radiat Oncol Biol Phys. 2024. PMID: 37802226 Clinical Trial.
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials.
Nikitas J, Ong WL, Carrier N, Romero T, Millar J, Steinberg ML, Rettig MB, Boutros PC, Reiter R, Nickols NG, Valle L, McGuire SE, Spratt DE, Souhami L, Roy S, Martin JM, Joseph D, Nabid A, Kishan AU. Nikitas J, et al. Int J Radiat Oncol Biol Phys. 2024 Jul 1;119(3):826-831. doi: 10.1016/j.ijrobp.2023.12.022. Epub 2023 Dec 25. Int J Radiat Oncol Biol Phys. 2024. PMID: 38151191 Clinical Trial.
Impact of PSMA PET on Prostate Cancer Management.
Weiner AB, Agrawal R, Valle LF, Sonni I, Kishan AU, Rettig MB, Raman SS, Calais J, Boutros PC, Reiter RE. Weiner AB, et al. Among authors: reiter re. Curr Treat Options Oncol. 2024 Feb;25(2):191-205. doi: 10.1007/s11864-024-01181-9. Epub 2024 Jan 25. Curr Treat Options Oncol. 2024. PMID: 38270802 Free PMC article. Review.
233 results